FATE THERAPEUTICS

Codice
FATE
Risorse esterne
Opinione della community
Prezzo Variazione Volume
3.06 -2.24 €
(-42.26%)
123694
P/E Obiettivo ad 1anno
0 5.83 €

Compra - Vendi

0
Tutte le tue transazioni per questo titolo

Devi effettuare l'accesso


Grafico

Altri utenti che hanno investito

Transations in last week
Buy: 4
Sell : 1

AngerManagement Gennaro Liguori

Commenti


Notizie

Technical Trading: Focus on Shares of Fate Therapeutics Inc. (FATE) - Rives Journal

Investors may be tracking certain levels on shares of Fate Therapeutics Inc. (FATE). The current 50-day Moving Average is 2.84, the 200-day Moving Average is 2.35, and the 7-day is noted at 2.99. Moving averages can help spot trends and price reversals.altro » Leggi

Next Weeks Broker Price Targets For Fate Therapeutics, Inc. (FATE) - Fiscal Standard

05/12/2015 – Fate Therapeutics, Inc. was downgraded to “hold” by analysts at Zacks. They now have a USD 6.25 price target on the stock. The share price of Fate Therapeutics, Inc. (FATE) was down -2.24% during the last trading session, with a day high ... Leggi

Where to From Here, Analysts Weigh in on Fate Therapeutics, Inc. (NASDAQ:FATE) - Liberty News

In the most recent trading session, Fate Therapeutics, Inc. (NASDAQ:FATE) shares saw a move of -3.51%. Covering Wall Street analysts have a consensus target price of $5.83 on the stock. Target predictions might differ vastly from analyst to analyst.altro » Leggi

Fate Therapeutics, Inc. (FATE) Receives Consensus Rating of “Buy ... - Sports Perspectives

Fate Therapeutics logo Fate Therapeutics, Inc. (NASDAQ:FATE) has been assigned a consensus recommendation of “Buy” from the seven analysts that are ... Leggi

Markets End Mostly Higher, How Did This Stock Fare: Fate Therapeutics, Inc. (NASDAQ:FATE) - Wall Street Beacon

Fate Therapeutics, Inc. (NASDAQ:FATE) performed nicely this week, continuing its impressive near-term upward movement. The stock has moved north 9.32% over the past week of trading. Looking further out, over the past twelve months, Fate Therapeutics, ...altro » Leggi

Fate Therapeutics, Inc. (FATE) Upgraded by Zacks Investment ... - The Cerbat Gem

Fate Therapeutics logo Fate Therapeutics, Inc. (NASDAQ:FATE) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report ...altro » Leggi

Trump Sworn In as S&P Declined, How Did this Stock Perform This Week: Fate Therapeutics, Inc. (NASDAQ:FATE) - Aiken Advocate

Fate Therapeutics, Inc. (NASDAQ:FATE) performed nicely this week, continuing its impressive near-term upward movement. The stock has moved north 10.87% over the past week of trading. Looking further out, over the past twelve months, Fate Therapeutics, ...altro » Leggi

Next Weeks Broker Price Targets For Fate Therapeutics, Inc. (FATE ... - Fiscal Standard

Stock market analysts and brokers have recently amended their target prices on shares of Fate Therapeutics, Inc. (FATE). According to the latest research ...altro » Leggi

Hochman Cole Investment Advisors adds Fate Therapeutics Inc (FATE) to its portfolio - Market Digest

Fate Therapeutics Inc closed down -0.06 points or -2.13% at $2.76 with 52,001 shares getting traded on Thursday. Post opening the session at $2.84, the shares hit an intraday low of $2.7 and an intraday high of $2.89 and the price fluctuated in this ...altro » Leggi

The Wedbush Comments on Fate Therapeutics, Inc.'s FY2018 ... - DailyQuint

Fate Therapeutics, Inc. (NASDAQ:FATE) – Equities research analysts at Wedbush issued their FY2018 earnings per share estimates for Fate Therapeutics in a ... Leggi